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Summary
COPD is a progressive pulmonary disease which may have a profound impact on general
health status and quality of life. This article presents data on the burden of COPD obtained
from the BREATHE study in the Middle East, North Africa and Pakistan. This study was
a large general population survey of COPD conducted in eleven countries of the region
using a standardised methodology. A total of 62,086 subjects were screened, of whom
2,187 fulﬁlled the “epidemiological” deﬁnition of COPD. Data on symptoms, perceived
disease severity, impact on work, limitations in activities and psychological distress were
collected. 1,392 subjects were analysable of whom 661 (47.5%) reported experiencing an
exacerbation of their respiratory condition, 49.4% reported comorbidities and 5.5% reported
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severe breathlessness as measured with the MRC breathlessness questionnaire. The degree
of breathlessness, as well as the perceived severity, was correlated with the overall
disease impact as measured with the COPD Assessment Test (p < 0.001). 374 subjects
(28.4%) reported that their respiratory condition prevented them from working and this
proportion rose to 47.8% in subjects who perceived their respiratory condition as severe.
47.9% of subjects reported difﬁculties in normal physical exertion, 37.5% in social activities
and 31.7% in family activities. Psychological distress was reported by between 42.3% and
53.2% of subjects, depending on the item. In conclusion, the burden of COPD is important,
and covers central aspects of daily life. For this reason, physicians should take time to discuss
it with their patients, and ensure that the management strategy proposed addresses all their
needs.
© 2012 Elsevier Ltd. All rights reserved.
Introduction
Chronic Obstructive Pulmonary Disease (COPD) is a major
cause of chronic morbidity and mortality worldwide.1 4 The
impact of COPD on health and quality of life is considerable,
particularly in patients with severe stages5,6 (GOLD 2009
stages 3 and 4,1 or GOLD 2011 groups C and D).7 It has also
been suggested that symptom burden in these is comparable
to that of patients with cancer, although patients with COPD
tend to live longer.8
The Confronting COPD international survey,6 published in
2002, which evaluated the impact of COPD in North America
and Europe, showed that COPD carried a signiﬁcant burden
to subjects, society and the economies of these countries.
For example, 44% of subjects in the USA with COPD in
this survey reported getting breathless when washing or
dressing, 51% reported that their symptoms limited their
ability to work, 52% felt that they were not in control of
their breathing.
In particular, the impact of COPD on work has been
investigated in several studies. For example, a study
comparing employees with COPD to those without COPD9
performed in the United States,9 indicated that the
former reported a signiﬁcantly lower quality of life with
worse mental and physical component summary scores
and health utilities and a greater decline in productivity,
more absenteeism, and more impairment in work and daily
activities than those without COPD. In addition, a higher
healthcare resource consumption was reported by employed
adults with COPD than by those employed without COPD,
particularly in those experiencing exacerbations.9,10
There are few studies assessing the burden of COPD in
developing countries. This lack of information may lead
to an underestimation of the real impact of the disease
and thus minimise the need for a holistic approach to
the management of COPD taking into account the burden
of the disease with respect to activities of daily living.
We have recently performed the BREATHE study, a large
epidemiological survey of subjects reporting COPD-related
symptoms in the general populations of eleven countries in
the Middle East and North Africa (MENA) region.11 This study
collected data on the subjects’ perception of COPD and
on the burden of disease in terms of work, daily activities
and psychological condition. This information was collected
using a similar questionnaire to that used in Confronting
COPD , which allows the ﬁndings to be compared with those
of the latter study.
Methods
The BREATHE study was a cross-sectional epidemiological
survey of COPD conducted in eleven countries (Algeria,
Egypt, Jordan, Lebanon, Morocco, Pakistan, Saudi Arabia,
Syria, Tunisia, Turkey and UAE) between June 2010 and
December 2011. A detailed description of the methodology
used in the study can be found in another article in
this supplement.11 The present article presents the data
obtained on the burden of the disease across the region.
Study sample
A general population sample of 10,000 subjects was
generated from random telephone numbers of each country
or zone of the MENA region. All subjects (men and women)
aged 40 years who agreed to participate in the study were
included and a structured telephone interview was carried
out with all eligible subjects. Subjects not domiciled in the
country or zone in question, or those of foreign origin who
had been resident in the country for <6 months at the time
of the study were excluded from the study, as were subjects
with comorbid mental illness.
Data collection
When initial telephone contact with each subject was
established, the interviewer explained the goal of the study
and the next steps. Subjects who agreed to participate in
the study completed a ﬁrst screening questionnaire which
collected data on demographics, respiratory symptoms and
smoking habits.11 13
Subjects were considered to have symptomatic COPD
if they fulﬁlled the two criteria for the epidemiological
deﬁnition of COPD used in this study and outlined in
the methodology paper.11 The ﬁrst criterion was EITHER
a diagnosis of COPD, emphysema or chronic bronchitis
OR the presence of coughing with phlegm or sputum
(productive cough), breathlessness or symptoms consistent
with chronic bronchitis. The second criterion was a lifetime
smoking exposure of 10 pack·years. Subjects in the COPD
population were considered as positively screened and were
invited to undergo a second more detailed telephone ques-
tionnaire on the disease (detailed COPD questionnaire). This
second questionnaire consisted of 77 questions collecting
information on risk factors, comorbidities, disease history,
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Box 1.
Which of the following best describes how breathless you get, these days?
Grade 1: Not troubled by breathlessness except on strenuous exercise
Grade 2: Short of breath when hurrying on the level or walking up a slight incline
Grade 3: Walk slower than most people on the level, stop after a mile or so, or stop after 15 minutes
walking at own pace
Grade 4: Stop for breath after walking about 100 yards or after a few minutes on level ground
Grade 5: Too breathless to leave the house, or breathless when undressing
Box 2.
Q14. Does your respiratory condition keep you from working?
Q15. Are you limited in the kind or amount of work you can do because of your respiratory condition?
Q16. Have you missed work in the past 12 months due to your respiratory condition?
Q17. How many work days have you lost in the past 12 months as a result of your respiratory condition?
Q18. Has your respiratory condition caused any other household member to miss work in the past 12 months?
clinical symptoms and burden and management of the
disease. Many of the items in this questionnaire, and notably
those related to burden of disease, were adopted from the
Confronting COPD study questionnaire.6
This detailed COPD questionnaire collected data on the
severity of breathlessness using the modiﬁed MRC (Medical
Research Council) breathlessness scale.14,15 Subjects were
asked to choose which of ﬁve statements, proposed in de-
creasing order of severity, best described their recent condi-
tion (Box 1). Each statement was assigned to a grade. Grades
1 and 2 indicated mild breathlessness, Grades 3 and 4 mod-
erate breathlessness and Grade 5 severe breathlessness.15
Overall symptom severity was also assessed with the COPD
Assessment Test (CAT),16,17 an eight-item patient-reported
outcome measure which scores severity on a forty-point
ordinal scale (0: no impairment; 40: high impairment). In
addition, data on the subject’s overall perception of severity
of COPD were also collected by asking a single question
‘Overall, how severe is your Respiratory Condition now? ’
with three proposed responses (mild, moderate or severe).
Information was also collected on disease exacerbations
in the previous six months. Since the BREATHE study
questionnaire addressed members of the general population
in non-medical terms, the number of exacerbations was not
explicitly documented and the presence of an exacerbation
was thus determined operationally. An exacerbation was
taken to have occurred in the previous six months if the
subject fulﬁlled any of the following criteria:
• Criterion 1: In the last 6 months, have you been told
by your physician that you have had worsening of your
“Respiratory Condition”? YES
• Criterion 2: In the last 6 months, have you been told by
your physician that you have had acute bronchitis? YES
• Criterion 3: In the last 6 months, what aspects of your
“Respiratory Condition” have worsened? (cough during the
daytime, cough during the night, phlegm, breathlessness
or shortness of breath and fatigue, ability to perform
regular activities) At least two symptoms cited
On the basis of their CAT score and their exacerbation
history (yes or no), subjects were assigned to one of four
severity grades according to an adaptation of the 2011 GOLD
classiﬁcation.7 GOLD group A consisted of subjects with a
CAT score <10 and without exacerbation, GOLD group B
concerned subjects with a CAT score 10 and without
exacerbation, GOLD group C those with a CAT score <10 and
with exacerbation and GOLD group D consisted of subjects
with a CAT score 10 and with exacerbation.
The impact of COPD on work was assessed using ﬁve items
(Box 2) in the detailed questionnaire. Question 14 had three
response modalities (Yes , No or Retired ). Questions 15
and 16 were only asked to subjects who replied ‘No ’ to
Question 14 and had two response modalities (Yes and No ).
Question 17 was only asked to subjects who replied ‘Yes ’ to
Question 16. Question 18 was asked to all subjects and had
two possible responses (Yes and No ).
The impact of COPD on subjects’ activities of daily living
and on a number of psychological variables was assessed
using two multi-item questions (Box 3) in the detailed COPD
questionnaire. The questions related to activities of daily
living had four possible response modalities (a lot , some ,
only a little or not at all ), which were concatenated into a
dichotomous variable (a lot or some versus only a little or
not at all). The questions related to psychological distress
had only two possible response modalities (Yes and No ).
Statistical analysis
Data presentation is principally descriptive, with continuous
variables being presented as mean values ±SEM and
categorical variables as frequency counts (%). Missing data
were not replaced and the relatively few subjects for whom
data were missing were excluded from the calculation
of frequency rates. The relationship between the MRC
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Box 3.
Q22. Would you agree with each of the following statements?
1. My cough or breathing is embarrassing in public
2. I expect my condition to get worse
3. I panic or get afraid when I cannot get my breath
4. I feel that I am not in control of my breathing problem
5. I often worry about having an exacerbation (increase in severity of symptoms) when I am away from
home
6. I have a hard time making plans because I never know how I will be feeling
7. The health care system could do a lot better job helping people with my condition
Q24. How much do you feel that your respiratory condition limits what you can do in each of the following areas?
Do you feel it restricts you a lot, some, only a little or not at all in
a. Sports and recreation
b. Normal physical exertion
c. Social activities
d. Sleeping
e. Housekeeping chores
f. Sexual intercourse
g. Famility activities
breathlessness scores and the CAT scores was assessed using
analysis of variance (ANOVA). The relationship between
different categorical variables and perceived severity was
determined using the c2 test and between perceived
severity and GOLD severity grade using log-linear analysis.
Variables assessing the impact of COPD on daily activities
(variables a to g) and on the psychological status (variables
1 to 7), as well as gender, overall severity, work impact and
CAT scores were entered into a Multiple Correspondence
Analysis (MCA) in order to identify relationships between
the different variables, and the ﬁndings displayed as a
factorial map. Close proximity between the centres of
gravity of two different variables on the factorial map is
indicative of a strong association between the variables,
and the separation between the centres of gravity of the
two response modalities (for example yes and no) of a given
variable is indicative of the discriminatory power of the
variable.
Results
Study sample
A total of 62,086 subjects completed the screening question-
naire. Of these, 2,187 subjects fulﬁlled the epidemiological
deﬁnition of COPD,11 of whom 1,392 (63.6%) completed the
detailed COPD subject questionnaire and constituted the
study population. No relevant differences in terms of age,
gender and COPD symptoms (productive cough, breathless-
ness or symptoms consistent with chronic bronchitis) were
found when comparing the COPD population who completed
the detailed questionnaire with all 2,187 subjects who
fulﬁlled the epidemiological deﬁnition of COPD.
The demographic features of the COPD population are
presented in Table 1. Three-quarters (75.6%) of the study
population were male (from 49.5% male in Lebanon to
96.2% in Algeria). Smoking 10 pack·years was part of the
epidemiological deﬁnition of COPD, and around two-thirds
of subjects were current smokers at the time of the survey
(range: 48.5% in Algeria to 82.4% in the UAE). A total of
696 subjects (50.1%) considered themselves to be in good,
very good or excellent health.
Symptom presentation
Symptom presentation in participating subjects in the
COPD population was documented with respect to onset
of exacerbations in the last six months and breathlessness.
Exacerbation history was established using the operational
deﬁnition provided in the Methods section. Overall, nearly
half of the study population (n = 661; 47.5% [95%CI:
44.9 50.1%]) reported experiencing an exacerbation of their
respiratory condition in the previous six months, ranging
from 36.0% [95%CI: 31.0 41.1%] in Turkey to 76.7% [95%CI:
61.5 91.8%] in Pakistan (Fig. 1).
COPD symptoms were evaluated using the MRC breathless-
ness questionnaire, which was completed by 1,091 subjects
(78.3%). The distribution of MRC breathlessness question-
naire grades is presented in Fig. 2. Overall, the most
frequently reported grade of breathlessness was “short of
breath when hurrying on the level or walking up a slight
incline” (Grade 2) by around one third of subjects (32.8%;
[95%CI: 30.1 35.7%]). Less than six percent of subjects
reported the highest breathlessness grade (too breathless
to leave the house). A positive association was observed
between the MRC breathlessness questionnaire grades and
CAT symptom severity scores (p < 0.001; r s = 0.293; Fig. 3).
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Figure 1. Rate of COPD exacerbations in participating countries of the MENA region. The deﬁnition of exacerbation used in our
study is described in the Methods section.
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Comorbidities
Around half (49.4%) of the study population reported having
comorbidities, ranging from 26.7% in Pakistan to 64.3% in
Jordan (Table 1). Speciﬁc information was collected with
respect to cardiovascular comorbidity, diabetes and asthma.
The proportion of subjects reporting these comorbidities
was 24.7% for cardiovascular disease, 17.8% for diabetes
and 7.1% for asthma. The extent of reporting of these
comorbidities was quite variable between countries, with
the proportion of patients reporting diabetes ranging from
6.7% in Pakistan to 30.6% in Saudi Arabia, and that of asthma
from 1.3% in Morocco to 20.8% in Pakistan.
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Figure 3. Relationship between scores of the MRC breathlessness scale and scores of the CAT questionnaire. Data are presented as
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Figure 4. Overall perceived severity of COPD symptoms by country.
Perceived severity of COPD symptoms
Data relating to the perceived severity of COPD (mild,
moderate or severe) were collected for 1,264 subjects and
are presented by country in Fig. 4. Overall, the majority
of subjects considered that their respiratory condition was
of moderate severity (57.5%) and around one third (31.7%)
considered it to be mild (Fig. 4). The highest proportions
of subjects considering their symptoms to be severe were
observed in the Maghreb countries and in Pakistan, and the
highest proportions of patients considering them mild in
Jordan, Morocco, Syria and Tunisia.
Perceived severity was also assessed according to
subjects’ demographics, CAT score and exacerbations, and
is summarised for all countries in Tables 2 and 3. The
perception of severity was not associated with age, gender
or the existence of comorbidities. However, subjects were
more likely to consider their symptoms to be moderate or
severe if they recalled having received a diagnosis of COPD
(p < 0.0001) and if they had experienced exacerbations
(p < 0.0001). In addition, mean CAT scores increased incre-
mentally with perceived severity (p < 0.0001) (Table 2).
Subjects with a higher grade of perceived severity were
more likely to have consulted a doctor, been hospitalised or
made an emergency room visit because of their respiratory
symptoms (p < 0.0001) (Table 3).
The relationship between perceived severity and GOLD
severity group was also evaluated. A total of 1,014 subjects
in the COPD population could be classiﬁed into one of
four groups (GOLD Group A, B, C and D) according to
CAT score and exacerbation history (Table 4). Subjects in
the higher-grade GOLD group reported having a more severe
condition (p < 0.0001) and a poorer general health status
(p < 0.0001). Overall, the relationship between perceived
severity and general health status on the one hand and
CAT scores and exacerbation on the other, appeared to
be stronger for CAT score than for exacerbations (0.0003
and 0.0238 respectively). Using a log-linear analysis for
a 3-way contingency table, a signiﬁcant association was
found between perceived severity on the one hand and both
exacerbations and CAT scores on the other (p < 0.001 in each
case).
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Table 2
Perceived severity according to subject characteristics
Mild (N = 401) Moderate (N = 727) Severe (N = 136) p
Age group
40 49 years 163 (40.6%) 289 (39.8%) 44 (32.4%)
50 59 years 142 (35.4%) 243 (33.4%) 53 (39.0%) 0.3774
60 years 96 (23.9%) 195 (26.8%) 39 (28.7%)
Gender
Men 304 (75.8%) 531 (73.0%) 99 (72.8%)
Women 97 (24.2%) 196 (27.0%) 37 (27.2%) 0.5702
COPD diagnosis 95 (23.7%) 271 (37.3%) 74 (54.4%) <0.0001
CAT Score 14.8±8.8 18.6±9.0 25.0±9.1 <0.0001
Exacerbations 157 (39.2%) 340 (46.8%) 94 (69.1%) <0.0001
Comorbidities 203 (50.6%) 355 (48.8%) 75 (55.1%) 0.3872
Table 3
Healthcare resource utilisation during the previous year according to perceived severity level
Mild (N = 401) Moderate (N = 727) Severe (N = 136) p
Consultations 243 (60.6%) 456 (62.7%) 106 (77.9%) 0.0001
Hospitalisations 57 (14.2%) 158 (21.7%) 61 (44.8%) <0.0001
Emergency visits 52 (13.0%) 142 (19.5%) 46 (33.8%) <0.0001
Table 4
Classiﬁcation of COPD subjects (n = 1,014) according to symptoms (CAT score) and exacerbation history
Variables Exacerbation
No
CAT score <10
Group A (N = 147)
CAT score 10
Group B (N = 233)
Yes
CAT score <10
Group C (N = 86)
CAT score 10
Group D (N = 548)
Perceived severitya
Mild 67 (52.8%) 78 (33.8%) 28 (32.6%) 125 (24.8%)
Moderate 58 (45.7%) 139 (60.2%) 29 (33.7%) 297 (58.9%)
Severe 2 (1.6%) 14 (6.1%) 3 (3.5%) 82 (16.3%)
General health status
Poor to very poor 14 (9.5%) 62 (26.6%) 7 (8.1%) 132 (24.1%)
Fair 30 (20.4%) 47 (20.2%) 23 (26.7%) 175 (31.9%)
Good to very good 81 (55.1%) 112 (48.1%) 49 (57.0%) 221 (40.3%)
Excellent 20 (13.6%) 12 (5.2%) 7 (8.1%) 20 (3.6%)
Comorbidities 66 (44.9%) 115 (49.4%) 38 (44.2%) 298 (54.4%)
a CAT scores were not documented for 20 subjects of Group A, 2 subjects of Group B, 26 subjects of Group C and
44 subjects of Group D. Percentages are calculated according to each resulting denominator.
Impact of respiratory symptoms
Work
Overall, 374 subjects (28.4%) reported that their respiratory
condition prevented them from working, and this proportion
rose to 47.8% in subjects who perceived their respiratory
condition as severe (Fig. 5). In those subjects who were in
full- or part-time employment, 21.5% (n = 125) reported that
they were limited in the kind or amount of work that they
could do and 17.2% (n = 103) reported having missed work
in the previous year due to their respiratory symptoms. The
mean number of days lost was 17.7±38.2. The proportion
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Figure 5. Impact on work activities according to the degree of perceived severity. Open bars: mild disease severity; grey bars:
moderate disease severity; black bars: severe disease severity. Data are presented for the 1,264 subjects providing data
on perceived disease severity and on impact on work.
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Figure 6. Percentage of COPD subjects reporting ‘some’ or ‘a lot’ of limitation with various activities. Data presented are the
mean values for all countries combined. The black bars indicate the inter-country range between the countries with the
lowest and the highest agreement rates.
of subjects reporting impaired work productivity or days
missing work also increased signiﬁcantly with perceived
disease severity (p < 0.0001) (Fig. 5). In addition, 102
respondents (8.1%) reported that their respiratory condition
had caused another member of their household to miss work
at least once in the previous year.
Limitations in activities of daily living
The reported impact of respiratory symptoms on activities of
daily living was assessed. Overall, a lot or some limitations
were reported for all areas of daily life considered in at least
thirty percent of subjects, ranging from 31.7% of subjects
limited in their family activities to 57.1% limited in sports
activities (Fig. 6). The impact of respiratory symptoms on
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Figure 7. Impact of respiratory symptoms on psychological variables. Data presented are the mean values for all countries
combined. The black bars indicate the inter-country range between the countries with the lowest and the highest
agreement rates.
each area was analysed according to whether the subject
reported having received a diagnosis of COPD and according
to the presence or absence of comorbidities. These analyses
showed that subjects who reported having received a
diagnosis of COPD reported limitations in all their daily
activities signiﬁcantly more often than those who did not
(p < 0.0162). In contrast, no signiﬁcant association between
the presence of comorbidities and limitations in activities
of daily living was observed, except for family activities,
which were more limited in subjects with comorbidities
(p = 0.0019).
Psychological distress
The impact of symptoms on a number of psychological
variables related to anxiety and distress was also evaluated.
Impact on all the psychological variables assessed was
reported by between forty and eighty percent of subjects
(Fig. 7). In addition, three-quarters of subjects considered
that the healthcare system could do more for them than
it does. Subjects who reported having received a diagnosis
of COPD were more likely to report an impact on all
psychological well-being items (p < 0.0026). In contrast,
no signiﬁcant association was observed between the
presence of comorbidities and psychological impact, with
the exception of the items related to anxiety about having
an exacerbation outside the house and to embarrassment
about cough or breathing in public (p < 0.005).
Factors associated with the burden of the disease
In order to identify factors potentially associated with the
burden of the disease, a multiple correspondence analysis
was performed. Variables assessing the impact of COPD
on subjects’ daily activities (variables a to g) and those
assessing psychological distress (variables 1 to 7), as well
as gender, overall severity and CAT scores were entered into
the analysis. The results are presented in Fig. 8. Disease
severity grades (panel A), whether measured by the CAT
or with the perceived severity, were well discriminated by
the horizontal axis of the factorial map and were aligned
along this dimension. The vertical axis discriminated the
severity items less well. Impact upon work was also aligned
along the horizontal axis. Female gender was associated
with more severe disease. The psychological distress items
(panel C) were all aligned with the severity grades, with
the presence of psychological distress being associated with
more severe disease. The individual psychological distress
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items were also closely associated with each other, except
for item 7 (the healthcare system could do a lot better
job helping people with my condition). The limitations
in activities of daily living items (Panel B) were also
discriminated by the horizontal (severity) axis with the
‘no or few limitations’ subgroups on the left-hand (low
severity) side of the factorial map. However, the limitations
items showed a different relationship with the vertical
axis to the severity and psychological distress items, with
the ‘no or few limitations’ subgroups lying in the upper
half and the ‘some or a lot of limitations’ in the lower
half of the map. This indicates that something other than
severity inﬂuences how subjects perceive limitations in their
daily activities. All individual limitations items were closely
associated with each other.
Discussion
The current study assessed the burden of COPD in a
representative sample of the general population of eleven
countries of the MENA region in 2011. The analysis was
performed in a total of 1,392 subjects fulﬁlling the
epidemiological deﬁnition of COPD and focuses on how they
perceived the severity of their COPD symptoms and how they
estimated the impact of these symptoms on their life. In this
large study population, respiratory symptoms signiﬁcantly
interfered with all activities of daily living assessed and thus
contribute to a signiﬁcant burden of disease. These ﬁndings
are consistent with the results of other studies such as the
Confronting COPD surveys in North America and Europe5,6
which used a similar methodology and questionnaire to the
BREATHE study (Table 5).
The impact of breathlessness was determined in the
BREATHE study using the MRC breathlessness questionnaire.
The 2011 GOLD guidelines7 propose that this scale may be
used as an alternative to the CAT for the assessment of
symptom severity in order to assign a severity grade and
thus identify the most appropriate management strategy,
although they consider the CAT to be the preferred option.
In this context, it is important that the CAT and the MRC
breathlessness questionnaire show substantial coherence.
In the BREATHE study sample of individuals in the general
population with COPD symptoms, the MRC breathlessness
questionnaire grade was shown to be positively associated
with the CAT score, which supports the idea that the
two measures are coherent. This is also consistent with a
large study of patients in primary care with spirometrically
Figure 8. Factorial analysis of variables potentially associated
with burden of disease. (A) Gender, diamond symbols; men
(light), women (dark); perceived severity, squares; mild (light);
moderate (medium); severe (dark); CAT score (triangles:
<10; (light), 10 20 (medium), 20 (dark); impact on work,
circles; no impact (light), impact (dark). (B) Limitations in
activities of daily living: a g correspond to items as deﬁned
in Box 2; square symbols: a lot or some limitations; diamond
symbols: a little or not at all limited. (C) Psychological distress
items: 1 7 correspond to items as deﬁned in Box 2; square
symbols: agree with the statement; diamond symbols: disagree
with the statement.
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Table 5
Comparison of the burden of COPD in the past yeara in the MENA region and in the United States5,20,21
BREATHE study
MENA region
Confronting COPD
USA5,20,21
MRC scale N = 1,091 N = 573
Grade 1 23.3% 15.0%
Grade 2 32.8% 25.0%
Grade 3 17.0% 17.0%
Grade 4 21.4% 32.0%
Grade 5 5.5% 8.0%
Perceived severity N = 1,264 N = 573
Mild 31.7% 34.0%
Moderate 57.5% 38.0%
Severe 10.8% 23.0%
Impact of COPD
Limitations in work N = 582 1,315b NA
Keeps from working 28.4% 34.0%
Limited kind or amount of work 21.5% 17.0%
Workdays lost in past year 17.2% 4.0%
Limitations in daily activities N = 1,210 1,258b NA
Sport and recreation 57.1% 72.0%
Normal physical exertion 47.9% 70.0%
Social activities 37.5% 53.0%
Sleeping 41.4% 50.0%
Household chores 38.8% 56.0%
Sexual intercourse 37.5% 37.0%
Family activities 31.7% 46.0%
Psychological distress N = 1,258 1,280b N = 573
My cough or breathing is embarrassing in public 42.3% 52.0%
I expect my condition to get worse 53.2% 66.0%
I panic or get afraid when I cannot get my breath 47.8% 58.0%
I feel that I am not in control of my breathing 51.6% 52.0%
I worry about having an exacerbation away from home 44.1% 39.0%
I have a hard time making plans 44.5% 48.0%
NA: not available.
a Values in boldface type indicate the most frequently cited responses for each domain.
b The number of responder subjects was different for each item: the range is provided.
deﬁned COPD,18 which reported very similar ﬁndings to the
present ones regarding the relationship between CAT score
and MRC breathlessness questionnaire grade, even though
this population was apparently more severe than the
BREATHE population. The observation of an association
between the CAT score and the different items of the MRC
breathlessness scale also supports the notion of a ‘ladder
of severity’ recently proposed by Jones et al.,19 whereby
increasing CAT scores are associated with more and more
limitations in activities.
Around half of the COPD population had experienced at
least one operationally-deﬁned exacerbation of their COPD
symptoms in the previous six months, and these subjects
reported a greater perceived severity of their respiratory
condition and a poorer general health status. The proportion
of patients with exacerbations identiﬁed using this deﬁnition
is within the range of that reported in other studies in
which exacerbations were ascertained by the physician.18,22
However, the operational deﬁnition used has not been
previously validated, and it would be useful to compare the
performance of this deﬁnition against physician-ascertained
exacerbations in a future study.
Half of the study population reported having comor-
bidities. This proportion was similar to that reported in
BREATHE study: Burden of COPD in the MENA region S57
two large cohorts from the US where 50.1% of COPD
subjects reported at least one comorbidity.23 Cardiovascular
comorbidities were reported by 24.7% of subjects and
diabetes by 17.8%. Asthma was reported by 7.1% of subjects.
These ﬁndings are comparable to those reported in many
other studies performed in the US and Europe.20,21,23,24
Nonetheless, it is probable that diabetes is under-reported
in the BREATHE population due to incomplete diagnosis,
since the proportions of affected subjects are generally
lower than prevalence rates for diabetes in subjects over
45 years of age reported in general population studies
in countries in the region.25 31 However, the between-
country variability in the proportion of subjects reporting
diabetes does reﬂect known regional variation in the
prevalence of diabetes, being highest in peninsular Arabia
and lower in Pakistan, Turkey and North Africa.32 There
is little published data on the prevalence of asthma in
the adult general population in countries of the region.
The proportion of subjects in the BREATHE study reporting
asthma was lower than adult prevalence estimates in
Morocco and Tunisia,33 again perhaps reﬂecting under-
diagnosis, but similar in Algeria.33 For Turkey, on the
other hand, the proportion of subjects with COPD reporting
comorbid asthma (10.4%) is higher than that reported in a
recent general population survey,34 and this may potentially
be explained by individuals with COPD believing that their
symptoms are due to asthma.
Overall, the percentage of subjects in the BREATHE
study reporting their symptoms to be of mild severity was
comparable with that observed in the Confronting COPD 5,6
study (31.7% versus 31.8%), although the proportion of
subjects reporting severe symptoms was lower in the
BREATHE study (10.4%) compared to the Confronting COPD
study (21.0%).5 These differences might be explained by
lower health expectations in the MENA region compared to
North America. This would be supported by the observation
that half of the BREATHE study population considered
themselves to be in excellent, very good or good health,
even though when asked about individual activities of daily
living, it was clear that the impact of their respiratory
condition on their lives was substantial, and equivalent to
that observed in the USA population of the Confronting
COPD study.5,20,23 Subjects with a higher grade of perceived
severity were more likely to have consulted a doctor, been
hospitalised or made an emergency room visit because of
their respiratory symptoms (p < 0.0001).
An association was observed between, on the one hand,
the severity of the respiratory condition perceived by the
patient and, on the other, the CAT score and the occurrence
of exacerbations. Nonetheless, in the BREATHE study as
well as in the Confronting COPD study,5,35,36 a considerable
disparity was observed between the degree of severity
of respiratory symptoms determined using the CAT or the
MRC scale and the subjective overall perception of its
severity reported by the subject. For example, in the
BREATHE study, 26.9% of subjects scored 4 or 5 on the MRC
breathlessness scale, consistent with severe COPD, whereas
only 5.9% perceived their symptoms to be severe. This
underestimation of perceived severity was also apparent in
Confronting COPD , in which 40% of subjects scored 4 or 5 on
the MRC breathlessness scale but only 23% of them perceived
their symptoms to be severe. Another international study
including Turkey, the COPD Uncovered study,10 found that
37.0% of interviewees fulﬁlled criteria for severe COPD using
the MRC breathlessness scale (Grade 4 or 5).
The perceived severity of COPD was not associated
with age or gender. This suggests that the symptoms
of COPD did not systematically worsen in elderly male
subjects, challenging the stereotypic image of the COPD
patient as an elderly male smoker. Nonetheless, since
over eighty percent of subjects in the BREATHE study
considered that their respiratory condition would inevitably
get worse with time, regardless of how it was managed,37
this lack of association between perceived severity and
age may also reﬂect adjustments in expectations about
what can be considered ‘normal’ respiratory health with
ageing. Moreover, and somewhat surprisingly, the presence
of comorbidities did not inﬂuence the grade of perceived
severity. This result differed from the one reported in the
COPD Uncovered 10 study where it was shown that subjects
with mild COPD reported less comorbidity than those with
more severe COPD.
The results of the BREATHE study indicate that COPD has
a substantial impact on work given that overall 28.4% of
subjects reported that their respiratory condition kept them
from working altogether. This percentage was consistent
with the ﬁndings of the COPD Uncovered study10 which
reported a rate of 26.0% and somewhat lower than that
described in the Confronting COPD survey in the United
States which reported a rate of 34.0%5,35,36 and in the
COPD-Life study38 in Turkey (45.3%, compared to 33.4% of
the Turkish subjects of the BREATHE study). However, it
should be noted that the economic consequences of stopping
work completely or of absenteeism in the region may be a
stronger disincentive than in the USA or Europe, where social
security protection is greater. Of those in work, around one
quarter were obliged to stop working for a mean number
of 17.8±38.2 days in the last year. Not surprisingly, the
proportion of subjects kept from working or who reported
an impact of their respiratory condition on their work was
higher in subjects with a higher disease severity. This is
consistent with ﬁndings reported in the literature, such as
in the COPD Uncovered study.10
The impact of symptoms on the daily activities and on
a number of psychological variables related to anxiety
and distress was also evaluated. Impact on all variables
assessed was reported by between thirty and sixty percent
of subjects, which is consistent with the results of the
Confronting COPD survey in the United States.5,35,36
Factorial analysis of the data suggested that limitations
in activities of daily living may represent a supplementary
dimension of burden of disease to severity. Psychological
distress, on the other hand, appeared to be closely related
to severity.
In conclusion, the burden of disease perceived by
subjects fulﬁlling the epidemiological deﬁnition of COPD was
important, and covered all aspects of daily life considered in
the survey. This burden may be underestimated in everyday
clinical practice due to the tendency of individuals to report
the perceived severity of their respiratory condition as less
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than it really is. For this reason, physicians should take time
to discuss the burden of respiratory symptoms on the daily
lives of their patients, and ensure that the management
strategy proposed addresses all the needs of the patient.
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